Q-omics provides the consensus-scored CDC5L profile across patient tissues and cancer cell-line models. CDC5L expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CDC5L is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CDC5L protein abundance shows 30,556 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where CDC5L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC5L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC5L survival associations across molecular data types. CDC5L RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC5L RNA expression–survival associations across cancer types. High CDC5L expression shows unfavorable associations in MESO and SARC, but favorable associations in KIRC, THYM, UCS and GBM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for CDC5L RNA expression.
This table summarizes CDC5L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC5L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC5L shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and LUAD. The HNSC box plot shows higher CDC5L RNA expression in tumor versus normal tissue (log2 FC = +0.620, t-test p < 0.001).
This table shows molecular features associated with CDC5L in patient tissues and cancer cell lines. In patient samples, CDC5L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC5L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
